Fractional Esterification Rate of Cholesterol and Ratio of Triglycerides to HDL-Cholesterol Are Powerful Predictors of Positive Findings on Coronary Angiography

Clinical Chemistry

Volumn 49, Issue 11, 2003, Pages 1873-1880

  Frohlich, Jiri ^a,c   Dobiášová, Milada ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b INSTITUTE OF PHYSIOLOGY   (Czech Republic)

^c ST PAUL S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; BIOCHEMICAL MARKER; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ALCOHOL CONSUMPTION; ANGIOCARDIOGRAPHY; ARTICLE; BLOOD PRESSURE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL ESTERIFICATION; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DIABETES MELLITUS; EXERCISE; FEMALE; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; RADIOASSAY; SMOKING; TRIACYLGLYCEROL BLOOD LEVEL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY ANGIOGRAPHY; CORONARY ARTERIOSCLEROSIS; ESTERIFICATION; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; REGRESSION ANALYSIS; TRIGLYCERIDES;

EID: 0242362621     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2003.022558     Document Type: Article

References (85)

1. Castelli WP. Lipids, risk factors and ischaemic heart disease. Atherosclerosis 1996;124(Suppl):S1-9.
2. Doll R. Fifty years of research on tobacco. J Epidemiol Biostat 2000;5:321-9.
3. Verges BL. Dyslipidaemia in diabetes mellitus. Review of the main lipoprotein abnormalities and their consequences on the development of atherogenesis. Diabetes Metab 1999;25(Suppl 3):32-40.
4. Kaplan NM. The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch Intern Med 1989;149:1514-20.
5. Gotto AM Jr. High-density lipoprotein cholesterol: an updated view. Curr Opin Pharmacol 2001;1:109-12.
6. Steinberg D, Gotto AM Jr. Preventing coronary artery disease by lowering cholesterol levels. JAMA 1999;282:2043-50.
7. Assmann G, Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Munster study. Am J Cardiol 1992;15:733-7.
8. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996;3:213-9.
9. Ooi TC, Ooi DS. The atherogenic significance of an elevated plasma triglyceride level. Crit Rev Clin Lab Sci 1998;35:489-516.
10. Koren E, Corder C, Mueller G, Centurion H, Hallum G, Fesmire J, et al. Triglyceride enriched lipoprotein particles correlate with the severity of coronary artery disease. Atherosclerosis 1996;122:105-15.
11. Drexel H, Aman FW, Rentsch K, Neunschwander C, Leuthy A, Khan SI, et al. Relation of the level of high-density lipoprotein subtractions to the presence and extent of coronary artery disease. Am J Cardiol 1992;70:436-40.
12. Campos H, Genest JJ Jr, Blijlevens E, McNamara JR, Jenner JL, Ordovas JM, et al. Low density lipoprotein particle size and coronary artery disease. Arterioscler Thromb 1992;12:187-95.
13. Sniderman AD, Furberg CD, Keech A, Roeters van Lennep JE, Frohlich J, Jungner I, et al. Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment. Lancet 2003;361:777-80.
14. Frohlich J, Dobiášová M, Lear S, Lee K. The role of risk factors in the development of atherosclerosis. Crit Rev Clin Lab Sci 2001;38:401-40.
15. Grundy SM, Pasternak R, Greenland P, Smith S Jr, Fuster V. AHA/ACC scientific statement. Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. J Am Coll Cardiol 1999;34:1348-59.
16. Assmann G, Cullen P, Schulte H. The Munster Heart Study (PROCAM): results of follow-up group at 8 years. Eur Heart J 1998;19(Suppl A):A2-11.
17. Dobiášová M, Frohlich J. Measurement of fractional esterification rate of cholesterol in plasma depleted of apoprotein B containing lipoprotein: methods and normal values. Physiol Res 1996;45:65-73.
18. Dobiášová M, Frohlich J. Assays of lecithin cholesterol acyltransferase (LCAT). In: Ordovas JM, ed. Methods in molecular biology. Lipoprotein protocols. Totowa, NJ: Humana Press, 1998:217-30.
19. 3H]cholesterol on values of esterification rate of cholesterol in apolipoprotein B depleted plasma. J Lipid Res 2000;41:1356-7.
20. HDL). Clin Biochem 2001;34:583-8.
21. Bolibar I, Thompson SG, von-Eckardstein A, Sandkamp M, Assmann G. Dose-response relationships of serum lipid measurements with the extent of coronary stenosis. Strong, independent, and comprehensive. ECAT Angina Pectoris Study Group. Arterioscler Thromb Vasc Biol 1995;15:1035-42.
22. Dobiášová M, Stříbrná J, Sparks DL, Pritchard PH, Frohlich J. Cholesterol esterification rates in very low density lipoprotein- and low density lipoprotein-depleted plasma: relation to high density lipoprotein subspecies, sex, hyperlipidemia and coronary artery disease. Arterioscler Thromb 1991;11:64-70.
23. Dobiášová M, Stříbrná J, Pritchard P, Frohlich J. Cholesterol esterification rate in plasma depleted of very low and low density lipoprotein is controlled by he proportion of HDL2 and HDL3 subclasses: study in hypertensive and normal middle aged and septuagenarian men. J Lipid Res 1992;33:1411-8.
24. Ohta T, Saku K, Takata K, Nagata N, Maung KK, Matsuda I. Fractional esterification rate of cholesterol in high density lipoprotein (HDL) can predict the particle size of low density lipoprotein and HDL in patients with coronary heart disease. Atherosclerosis 1997;135:205-12.
25. Williams PT, Superko HR, Haskell WL, Alderman EL, Blanche PJ, Holl LG, et al. Smallest LDL particles are most strongly related to coronary disease progression in men. Arterioscler Thromb Vasc Biol 2003;23:314-21.
26. Rosenson RS, Otvos JD, Freedman DS. Relations of lipoprotein subclass levels and low-density lipoprotein size to progression on coronary artery disease in the Provastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-I) trial. Am J Cardiol 2002;90:89-94.
27. Hong MK, Romm PA, Reagan K, Green CE, Rackley CE. Usefulness of the total cholesterol to high-density lipoprotein cholesterol ratio in predicting angiographic coronary artery disease in women. Am J Cardiol 1991;68:1646-50.
28. Luria MH, Erel J, Sapoznikov D, Gotsman MS. Cardiovascular risk factor clustering and ratio of total cholesterol to high-density lipoprotein cholesterol in angiographically documented coronary artery disease. Am J Cardiol 1991;67:31-6.
29. Kwiterovich PO Jr. Clinical relevance of the biochemical, metabolic, and genetic factors that influence low-density lipoprotein heterogeneity. Am J Cardiol 2002;90:30i-47i.
30. Miller N. Association of high-density lipoprotein subclasses and apolipoproteins with ischemic heart disease and coronary atherosclerosis. Am Heart J 1987;113:589-97.
31. Brown BG, Zhao XQ, Chait A, Fisher LD, Cheung MC, Morse JS, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001;345:1583-92.
32. O'Sullivan JJ, Matthew A, Conroy RM, Erwin RJ, Duggan PF. Relation of angiographically defined coronary artery disease to serum lipoprotein levels. Clin Cardiol 1990;13:841-4.
33. Yang T, Doherty TM, Wong ND, Detrano RC. Alcohol consumption, coronary calcium, and coronary heart disease events. Am J Cardiol 1999;84:802-6.
34. Inoue T, Uchida T, Kamishirado H, Takayanagi K, Morooka S. Antibody against oxidized low density lipoprotein may predict progression or regression of atherosclerotic coronary artery disease. J Am Coll Cardiol 2001;37:1871-6.
35. Pan QX, Liu P, Wang SC, Pan JT, Sun BY, Wu XY, et al. The study of serum apoprotein levels as indicators for the severity of angiographically assessed coronary artery disease. Am J Clin Pathol 1991;95:597-600.
36. Reinhart RA, Gani K, Arndt MR, Broste SK. Apolipoproteins A-I and B as predictors of angiographically defined coronary artery disease. Arch Intern Med 1990;150:1629-33.
37. Ford ES, Cooper RS, Simmons B, Castaner A. Serum lipids, lipoproteins and apolipoproteins in black patients with angiographically defined. J Clin Epidemiol 1990;43:425-32.
38. McGill DA, Talsma P, Ardlie NG. Relationship of blood cholesterol and apoprotein B levels to angiographically defined coronary artery disease in young males. Coron Artery Dis 1993;4:261-70.
39. Westerveld HT, van Lennep JE, van Lennep HW, Liem AH, de Boo JA, van de Schouw YT, et al. Apolipoprotein B and coronary artery disease in women: a cross-sectional study in women. Arterioscler Thromb Vasc Biol 1998;18:1101-7.
40. Sahi N, Pahlajani DB, Sainani GS. Apolipoproteins A-1 and B as predictors of angiographically assessed coronary artery disease. J Assoc Physicians India 1993;41:713-5.
41. KorhonenT, Savolainen MJ, Koistinen MJ, Ikaheimo M, Linnaluoto MK, Kervinen K, et al. Association of lipoprotein cholesterol and triglycerides with the severity of coronary artery disease in men and women. Atherosclerosis 1996;127:213-20.
42. Schwertner HA, Fischer JR Jr. Comparison of various lipid, lipoprotein, and bilirubin combinations as risk factors for predicting coronary artery disease. Atherosclerosis 2000;150:381-7.
43. Guerci AD, Spadaro LA, Goodman KJ, Lledo-Perez A, Newstein D, Lerner G, et al. Comparison of electron beam computed tomography scanning and conventional risk factor assessment for the prediction of angiographic coronary artery disease. J Am Coll Cardiol 1998;32:673-9.
44. Bhatnagar D, Durrington PN, Channon KM, Prais H, Mackness MI. Increased transfer of cholesteryl esters from high density lipoproteins to low density and very low density lipoproteins in patients with angiographic evidence of coronary artery disease. Atherosclerosis 1993;98:25-32.
45. Erren M, Reinecke H, Junker R, Fobker M, Schulte H, Schurek JO, et al. Systemic inflammatory parameters in patients with atherosclerosis of the coronary and peripheral arteries. Arterioscler Thromb Vasc Biol 1999;19:2355-63.
46. Saku K, Zhang B, Ohta T, Arakawa KJ. Quantity and function of high density lipoprotein as an indicator of coronary atherosclerosis. Am Coll Cardiol 1999;33:436-43.
47. Marshall HW, Morrison LC, Wu LL, Anderson JL, Corneli PS, Stauffer DM, et al. Apolipoprotein polymorphisms fail to define risk of coronary artery disease. Results of a prospective, angiographically controlled study. Circulation 1994;89:567-77.
48. Fujiwara R, Kutsumi Y, Hayashi T, Kim SS, Misawa T, Tada H, et al. Metabolic risk factors in the normolipidemic male patients with angiographically defined coronary artery disease. Jpn Circ J 1990;54:493-500.
49. Smuts CM, Weich HF, Weight MJ, Faber M, Kruger M, Lombard CJ, et al. Free cholesterol concentrations in the high-density lipoprotein subfraction-3 as a risk indicator in patients with angiographically documented coronary artery disease. Coron Artery Dis 1994;5:331-8.
50. Reedman DS, Croft JB, Anderson AJ, Byers T, Jacobsen SJ, Gruchow HW, et al. The relation of documented coronary artery disease to levels of total cholesterol and high-density lipoprotein cholesterol. Epidemiology 1994;5:80-7.
51. Johansson J, Carlson LA, Landou C, Hamsten A. High density lipoproteins and coronary atherosclerosis. A strong inverse relation with the largest particles is confined to normotriglyceridemic patients. Arterioscler Thromb 1991;11:174-82.
52. French JK, Elliott JM, Williams BF, Nixon DJ, Denton MA, White HD. Association of angiographically detected coronary artery disease with low levels of high-density lipoprotein cholesterol and systemic hypertension. Am J Cardiol 1993;71:505-10.
53. Violaris AG, Melkert R, Serruys PW. Influence of serum cholesterol and cholesterol subfractions on restenosis after successful coronary angioplasty. A quantitative angiographic analysis of 3336 lesions. Circulation 1994;90:2267-79.
54. Arteaga A, Martinez A, Pollak F, Borghesi L, Catalan L, Acosta AM, et al. Indicators of atherosclerosis risk. Evaluation with coronary angiography in non diabetic men with total cholesterol levels equal to or below 240 mg/dl]. Rev Med Chil 1995;123:145-57.
55. Romm PA, Green CE, Reagan K, Rackley CE. Relation of serum lipoprotein cholesterol levels to presence and severity of angiographic coronary artery disease. Am J Cardiol 1991;67:479-83.
56. Miwa K, Nakagawa K. Risk factors that discriminate 'high-risk' from 'low-risk' Japanese patients with coronary artery disease. Jpn Circ J 2000;64:825-30.
57. MillerM, Mead LA, Kwiterovich PO Jr, Pearson TA. Dyslipidemias with desirable plasma total cholesterol levels and angiographically demonstrated coronary artery disease. Am J Cardiol 1990;65:1-5.
58. Nikkila M, Koivula T, Niemela K, Sisto T. High density lipoprotein cholesterol and triglycerides as markers of angiographically assessed coronary artery disease. Br Heart J 1990;63:78-81.
59. Sutherland WH, Restieaux NJ, Nye ER, Williams MJ, de Jong SA, Robertson MC, et al. IDL composition and angiographically determined progression of atherosclerotic lesions during simvastatin therapy. Arterioscler Thromb Vasc Biol 1998;18:577-83.
60. Negri M, Sheiban I, Arigliano PL, Tonni S, Montresor G, Carlini S, et al. Interrelation between angiographic severity of coronary artery disease and plasma levels of insulin, C-peptide and plasminogen activator inhibitor-1. Am J Cardiol 1993;72:397-401.
61. Ley CJ, Swan J, Godsland IF, Walton C, Crook D, Stevenson JC. Insulin resistance, lipoproteins, body fat and hemostasis in nonobese men with angina and a normal or abnormal coronary angiogram. J Am Coll Cardiol 1994;23:377-83.
62. Tribouilloy CM, Peltier M, Iannetta-Peltier MC, Zhu Z, Andrejak M, Lesbre JP. Relation between low-density lipoprotein cholesterol and thoracic aortic atherosclerosis. Am J Cardiol 1999;84:603-5,A9.
63. Miller BD, Alderman EL, Haskell WL, Fair JM, Krauss RM. Predominance of dense low-density lipoprotein particles predicts angiographic benefit of therapy in the Stanford Coronary Risk Intervention Project. Circulation 1996;94:2146-53.
64. Griffin BA, Freeman DJ, Tait GW, Thomson J, Caslake MJ, Packard CJ, et al. Role of plasma triglyceride in the regulation of plasma low density lipoprotein (LDL) subfractions: relative contribution of small, dense LDL to coronary heart disease risk. Atherosclerosis 1994;106:241-53.
65. Linden T, Taddei-Peters W, Wilhelmsen L, Herlitz J, Karlsson T, Ullstrom C, et al. Serum lipids, lipoprotein(a) and apo(a) isoforms in patients with established coronary artery disease and their relation to disease and prognosis after coronary by-pass surgery. Atherosclerosis 1998;137:175-86.
66. O'Brien T, Nguyen TT, Hallaway BJ, Hodge D, Bailey K, Holmes D, et al. The role of lipoprotein A-I and lipoprotein A-I/A-II in predicting coronary artery disease. Arterioscler Thromb Vasc Biol 1995;15:228-31.
67. Alaupovic P, Mack WJ, Knight-Gibson C, Hodis HN. The role of triglyceride-rich lipoprotein families in the progression of atherosclerotic lesions as determined by sequential coronary angiography from a controlled clinical trial. Arterioscler Thromb Vasc Biol 1997;17:715-22.
68. Wilson SH, Celermajer DS, Nakagomi A, Wyndham RN, Janu MR, Ben Freedman S. Vascular risk factors correlate to the extent as well as the severity of coronary atherosclerosis. Coron Artery Dis 1999;10:449-53.
69. Karpe F, Taskinen MR, Nieminen MS, Frick MH, Kesaniemi YA, Pasternack A, et al. Remnant-like lipoprotein particle cholesterol concentration and progression of coronary and vein-graft atherosclerosis in response to gemfibrozil treatment. Atherosclerosis 2001;157:181-7.
70. Masuoka H, Ishikura K, Kamei S, Obe T, Seko T, Okuda K, et al. Predictive value of remnant-like particles cholesterol/high-density lipoprotein cholesterol ratio as a new indicator of coronary artery disease. Am Heart J 1998;136:226-30.
71. Hearn JA, DeMaio SJ Jr, Roubin GS, Hammarstrom M, Sgoutas D. Predictive value of lipoprotein (a) and other serum lipoproteins in the angiographic diagnosis of coronary artery disease. Am J Cardiol 1990;66:1176-80.
72. Wang XL, Tam C, McCredie RM, Wilcken DE. Determinants of severity of coronary artery disease in Australian men and women. Circulation 1994;89:1974-81.
73. Patsch JR, Miesenbock G, Hopferwieser T, Muhlberger V, Knapp E, Dunn JK, et al. Relation of triglyceride metabolism and coronary artery disease. Studies in the postprandial state. Arterioscler Thromb 1992;12:1336-45.
74. Nielsen NE, Olsson AG, Swahn E. Plasma lipoprotein particle concentrations in postmenopausal women with unstable coronary artery disease. Analysis of diagnostic accuracy using receiver operating characteristics. J Intern Med 2000;247:43-52.
75. Hodis HN, Mack WJ, Azen SP, Alaupovic P, Pogoda JM, LaBree L, et al. Triglyceride- and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin. Circulation 1994;90:42-9.
76. Phillips NR, Waters D, Havel RJ. Plasma lipoproteins and progression of coronary artery disease evaluated by angiography and clinical events. Circulation 1993;88:2762-70.
77. Tkac I, Kimball BP, Lewis G, Uffelman K, Steiner G. The severity of coronary atherosclerosis in type 2 diabetes mellitus is related to the number of circulating triglyceride-rich lipoprotein particles. Arterioscler Thromb Vasc Biol 1997;17:3633-8.
78. Syvanne M, Pajunen P, Kahri J, Lahdenpera S, Ehnholm C, Nieminen MS, et al. Determinants of the severity and extent of coronary artery disease in patients with type-2 diabetes and in nondiabetic subjects. Coron Artery Dis 2001;12:99-106.
79. Hodis HN, Mack WJ. Triglyceride-rich lipoproteins and progression of atherosclerosis. Eur Heart J 1998;19(Suppl A):A40-4.
80. Mack WJ, Krauss RM, Hodis HN. Lipoprotein subclasses in the Monitored Atherosclerosis Regression Study (MARS). Treatment effects and relation to coronary angiographic progression. Arterioscler Thromb Vasc Biol 1996;16:697-704.
81. Tornvall P, Bavenholm P, Landou C, de Faire U, Hamsten A. Relation of plasma levels and composition of apolipoprotein B-containing lipoproteins to angiographically defined coronary artery disease in young patients with myocardial infarction. Circulation 1993;88(5 Pt 1):2180-9.
82. Lemieux I, Pascot A, Couillard C, Lamarche B, Tchernof A, Almeras N, et al. Hypertriglyceridemic waist: a marker of the atherogenic metabolic triad (hyperinsulinemia; hyperapolipoprotein B; small, dense LDL) in men? Circulation 2000;102:179-84.
83. Vakkilainen J, Steiner G, Ansquer JC, Aubin F, Rattier S, Foucher C, et al. DAIS Group. Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention Study (DAIS). Circulation 2003;107:1733-7.
84. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): final report. Circulation 2002;106:3143-421.
85. Francis MC, Frohlich JJ. Coronary artery disease in patients at low risk - apolipoprotein AI as an independent risk factor. Atherosclerosis 2001;155:165-70.